Meta-analysis: Ribavirin-induced haemolytic anaemia in patients with chronic hepatitis C

Alimentary Pharmacology and Therapeutics

Volumn 16, Issue 9, 2002, Pages 1623-1632

  Chang, C H ^a   Chen, K Y ^a   Lai, M Y ^a   Chan, K A ^b  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ALPHA2A INTERFERON; ALPHA2B INTERFERON; HEMOGLOBIN; RIBAVIRIN;

ADULT; ARTICLE; CHRONIC HEPATITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEMOLYTIC ANEMIA; HEPATITIS C; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDLINE; META ANALYSIS; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; RISK FACTOR;

ADULT; ANEMIA, HEMOLYTIC; ANTIVIRAL AGENTS; FEMALE; HEPATITIS C, CHRONIC; HUMANS; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS; RIBAVIRIN;

EID: 0036733269     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.2002.01326.x     Document Type: Article

References (33)

1. Recovery, persistence, and sequelae in hepatitis C virus infection: A perspective on long-term outcome
2. Hepatitis C virus infection
3. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C
4. Randomized trial of interferonα2b plus ribavirin for 48 weeks or for 24 weeks versus interferonα2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus
5. Treatment of chronic hepatitis C
6. Severe anaemia following combined α-interferon/ribavirin therapy of chronic hepatitis C
7. Hemolytic anaemia and the treatment of chronic hepatitis C
8. Factors influencing ribavirin-induced haemolysis
9. Combination therapy with interferon plus ribavirin for the initial treatment of chronic hepatitis C
10. Safety of combination interferon alfa-2b/ribavirin therapy in chronic hepatitis C-relapsed and treatment-naive patients
11. Interferon and ribavirin vs interferon alone in the re-treatment of chronic hepatitis C previously non-responsive to interferon. A meta-analysis of randomized trials
12. Incorporating variations in the quality of individual randomized trials into meta-analysis
13. Meta-analysis in clinical trials
14. Interferon-α plus ribavirin in chronic hepatitis C resistant to previous interferon-α course: Results of a randomized multicenter trial
15. Interferon-α-2B and ribavirin in combination for chronic hepatitis C patients not responding to interferon-α alone: An Italian multicenter, randomized, controlled, clinical study
16. Interferon alpha-2B and ribavirin in combination for patients with chronic hepatitis C who failed to respond to, or relapsed after, interferon alpha therapy: A randomized trial
17. Treatment with interferon-alpha2a alone or interferon-alpha2a plus ribavirin in patients with chronic hepatitis C previously treated with interferon-alpha2a
18. A pilot study of combination therapy with ribavirin plus interferon alfa for interferon alfa-resistant chronic hepatitis C
19. The effect of interferon alfa and ribavirin combination therapy in naive patients with chronic hepatitis C
20. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C
21. Ribavirin as therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial
22. Ribavirin treatment for patients with chronic hepatitis C: Results of a placebo-controlled study
23. A pilot study of ribavirin and interferon beta for the treatment of chronic hepatitis C
24. Ribavirin and interferon alfa-2b in chronic hepatitis C: Assessment of possible pharmacokinetic and pharmacodynamic interactions
25. Long-term efficacy of ribavirin plus interferon alfa in the treatment of chronic hepatitis C
26. Randomised, double-blind, placebo-controlled trial of interferonα-2b with and without ribavirin for chronic hepatitis C
27. Interferon versus ribavirin plus interferon in chronic hepatitis C previously resistant to interferon: A randomized trial
28. Sequential versus concomitant administration of ribavirin and interferon alfa-n3 in patients with chronic hepatitis C not responding to interferon alone: Results of a randomized, controlled trial
29. Ribavirin enhances the efficacy but not the adverse effects of interferon in chronic hepatitis C. Meta-analysis of individual patient data from European centers
30. Interferon-ribavirin for chronic hepatitis C with and without cirrhosis: Analysis of individual patient data of six controlled trials
31. Invited commentary: A critical look at some popular meta-analytic methods
32. Combination therapy with interferon alpha and ribavirin for chronic hepatitis C virus infection in thalassaemic patients
33. Hemolytic anaemia by ribavirin therapy in patients with chronic hepatitis C virus infection: Role of membrane oxidative damage